Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.54 |
| ▸ | TLR2 | O60603 | 5/20 | 0.53 |
| ▸ | ACHE | P22303 | 6/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25005592 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3TLR2ACHELPAR2 | |
| SCHEMBL24435889 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3TLR2ACHELPAR2 | |
| SCHEMBL15160078 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3TLR2ACHELPAR2 | |
| SCHEMBL24470493 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3TLR2ACHELPAR2 | |
| SCHEMBL17431977 | 0.94 | ACHE (0.59) | LPAR1LPAR3TLR2ACHE | |
| SCHEMBL15158621 | 0.94 | ACHE (0.55) | LPAR1LPAR3TLR2ACHELPAR2 | |
| SCHEMBL15160079 | 0.94 | ACHE (0.55) | LPAR1LPAR3TLR2ACHELPAR2 | |
| SCHEMBL10819280 | 0.94 | ACHE (0.55) | LPAR1LPAR3TLR2ACHELPAR2 | |
| SCHEMBL17733481 | 0.91 | ACHE (0.57) | LPAR1LPAR3TLR2ACHE | |
| SCHEMBL16023973 | 0.91 | ACHE (0.57) | LPAR1LPAR3TLR2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283333-B2 | Lipid formulations for nucleic acid delivery | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-10-09 | — | — | US | disclosed |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-07-05 | — | — | US | disclosed |
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | LPAR1 38/4885LPAR3 69/4885TLR2 2280/4885 |
| US-20120172411-A1 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF | NPC1L1, LDLR, CETP | LPAR1 101/4885LPAR3 74/4885TLR2 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.